Related Experiment Videos

Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis

M S Rouse1, R M Wilcox, N K Henry

  • 1Mayo Clinic and Foundation, Mayo Medical School, Rochester, Minnesota 55905.

Insights

Ciprofloxacin and rifampin showed superior efficacy over vancomycin for treating Staphylococcus epidermidis endocarditis. Combination therapies including ciprofloxacin or rifampin were also effective, with limited resistance development.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Staphylococcus epidermidis is a common cause of healthcare-associated infections, particularly endocarditis.
  • Effective antimicrobial therapy is crucial for managing S. epidermidis endocarditis.
  • Vancomycin is a standard treatment, but resistance and treatment failures necessitate exploring alternative agents.

Purpose of the Study:

  • To compare the efficacy of ciprofloxacin and rifampin against vancomycin for experimental Staphylococcus epidermidis endocarditis.
  • To evaluate combination antimicrobial therapies including ciprofloxacin and rifampin.
  • To assess the development of antimicrobial resistance during treatment.

Main Methods:

  • Experimental endocarditis model in animals.
  • Treatment with ciprofloxacin, rifampin, vancomycin, gentamicin, and various combinations.
  • Assessment of treatment efficacy and detection of resistant S. epidermidis strains.

Main Results:

  • Ciprofloxacin and rifampin were significantly more effective than vancomycin or vancomycin plus gentamicin.
  • No significant differences in efficacy were observed among regimens containing ciprofloxacin or rifampin.
  • Rifampin resistance emerged in two animals; no other resistance was detected.

Conclusions:

  • Ciprofloxacin, alone or with rifampin, represents an effective therapeutic option for S. epidermidis endocarditis.
  • Rifampin-containing regimens should be used cautiously due to potential resistance development.
  • Further research into optimal combination therapies and resistance monitoring is warranted.

Related Concept Videos